Reported Earlier, FDA Issues Warning To Cue Health Over Emergency Use Authorized (EUA) COVID-19 Test
Portfolio Pulse from Benzinga Newsdesk
The FDA has issued a warning to Cue Health regarding its Emergency Use Authorized COVID-19 test. The company is reviewing the letter and will respond soon.
May 14, 2024 | 7:53 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cue Health received a warning from the FDA about its COVID-19 test, which is under Emergency Use Authorization. The company is currently assessing the FDA's concerns and planning its response.
Receiving a warning from the FDA is a significant regulatory challenge that can affect a company's product credibility and future sales. For Cue Health, this could lead to increased scrutiny, potential financial penalties, or requirements for corrective action, all of which could negatively impact the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100